Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-analysis.
Lasse de Fries JensenVasileios AntavalisJan Odgaard-JensenAnnachiara RossiAlberto PietropoliMichael HøjbyPublished in: Advances in therapy (2024)
No efficacy and safety differences were identified in comparisons of once weekly somapacitan versus somatrogon and lonapegsomatropin, as well as daily GH. All treatments were generally well tolerated, with the exception of observed injection site pain for somatrogon.